BridgeBio Pharma (BBIO) Stock Price, News & Analysis

Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $32.97 to $33.93
• 50-Day Range: $30.14 to $38.57
• 52-Week Range: $21.62 to $39.54
• Volume: 1.57 million shs
• Average Volume: 2.44 million shs
• Market Capitalization: $6.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.09
• Consensus Rating: Moderate Buy

BridgeBio Pharma Stock Analysis - MarketRank™

BridgeBio Pharma scored higher than 90% of companies evaluated by MarketBeat, and ranked 89th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

BridgeBio Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.67) to ($2.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BridgeBio Pharma is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BridgeBio Pharma is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.68% of the outstanding shares of BridgeBio Pharma have been sold short.

Short Interest Ratio / Days to Cover

BridgeBio Pharma has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in BridgeBio Pharma has recently decreased by 0.58%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BridgeBio Pharma does not currently pay a dividend.

Dividend Growth

BridgeBio Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.31

Percentage of Shares Shorted

11.68% of the outstanding shares of BridgeBio Pharma have been sold short.

Short Interest Ratio / Days to Cover

BridgeBio Pharma has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in BridgeBio Pharma has recently decreased by 0.58%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 1.03

News Sentiment

BridgeBio Pharma has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for BridgeBio Pharma this week, compared to 9 articles on an average week.

Search Interest

15 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $416,921,291.00 in company stock.

Percentage Held by Insiders

18.20% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BBIO Stock Analysis - Frequently Asked Questions

How have BBIO shares performed this year?

BridgeBio Pharma's stock was trading at $27.44 at the start of the year. Since then, BBIO shares have increased by 20.6% and is now trading at $33.10.
View the best growth stocks for 2025 here.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced its quarterly earnings data on Tuesday, April, 29th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.12. BridgeBio Pharma's quarterly revenue was down 44.8% on a year-over-year basis.
Read the conference call transcript.

When did BridgeBio Pharma IPO?

BridgeBio Pharma (BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

Who are BridgeBio Pharma's major shareholders?

Top institutional shareholders of BridgeBio Pharma include Vanguard Group Inc. (7.85%), Alliancebernstein L.P. (1.41%), Invesco Ltd. (1.16%) and Cormorant Asset Management LP (1.05%). Insiders that own company stock include Global Investors Lp Viking, Genetic Disorder LP Kkr, Neil Kumar, Frank Mccormick, Maricel Apuli, Brian C Stephenson, Andrea Ellis, Randal W Scott and Hannah Valantine.
View institutional ownership trends.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BBIO
• CIK: 1743881
• Web: bridgebio.com
• Phone: (650) 391-9740
• Fax: N/A
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $57.09
• High Stock Price Target: $95.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +72.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$535.76 million
• Net Margins: -241.44%
• Pretax Margin: -244.34%
• Return on Equity: N/A
• Return on Assets: -75.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.67
• Quick Ratio: 4.67

Sales & Book Value

• Annual Sales: $127.42 million
• Price / Sales: 49.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.71) per share
• Price / Book: -4.29

Miscellaneous

• Outstanding Shares: 189,881,000
• Free Float: 143,288,000
• Market Cap: $6.29 billion
• Optionable: Optionable
• Beta: 1.15